Stay in the know. Connect with your peers and hear the latest hepatic encephalopathy (HE) research at upcoming live and virtual events.

Please note that the status of scientific meetings may change at any time. Please visit the organization or meeting website for the latest updates regarding occurrence and scheduling.

Digestive Disease Week® (DDW 2021)

Digestive Disease Week® (DDW 2021)

Location: Virtual Date: May 21–23, 2021

Attend the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Event details & registration

American Academy of Physician Assistants Conference (AAPA 2021)

American Academy of Physician Assistants Conference (AAPA 2021)

Location: Virtual Date: May 23–26, 2021

Shape your future with networking events and leadership training. Advance your patient care with new clinical skills. Challenge yourself to make new connections and do your part to bring down practice barriers for PAs.

Event details & registration

American Association of Nurse Practitioners National Conference (AANP 2021)

American Association of Nurse Practitioners National Conference (AANP 2021)

Location: Virtual Date: June 15, 2021 – August 31, 2021

Find opportunities for collegial networking with thousands of NPs at the largest annual event providing educational content for NPs of all specialties.

Event details & registration

The International Liver Congress (ILC 2021)

The International Liver Congress (ILC 2021)

Location: Virtual Date: June 23–26, 2021

Attendees will hear the latest in epidemiological and real-world data on liver disease and gain a deeper understanding of the underlying mechanisms. Leading clinicians and researchers in the field will talk about daily interactions with patients, to help with or even reverse liver disease, and updates on treatment options.

Event details & registration

World Congress of Gastroenterology (WCOG 2021)

World Congress of Gastroenterology (WCOG 2021)

Location: Dubai, United Arab Emirates Date: December 12–15, 2021

The World Congress of Gastroenterology 2021 will be held in partnership with the Emirates Gastroenterology and Hepatology Society.

Event details & registration
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.